Sinorui Medical Completes Angel Funding Round to Establish Quantitative Neurological Function Assessment as the Gold Standard

VCBeat has learned that Zhongke Ruiyi recently completed its angel round of financing, co-led by LCIG and ZhenFund, with Changjian Investment participating as a follow-on investor. The funds raised in this round will be used for team building, product research and development, and the registration and filing of medical devices.

Zhongke Ruiyi is an innovative, fast-growing medical technology enterprise incubated by the Chinese Academy of Sciences (CAS). Leveraging frontier neuroscience achievements that have received the National Science and Technology Progress Award, and pooling the R&D strengths of the CAS Institute of Software and Peking Union Medical College Hospital, the company provides intelligent solutions covering the full spectrum of screening, diagnosis, treatment, and research for neurological disorders.

Currently, Zhongke Ruiyi has developed two solutions: quantitative assessment of motor function and quantitative evaluation of cognitive function. These solutions will serve as infrastructure for neurology departments in hospitals at all levels, assisting physicians in more objectively assessing, screening, diagnosing, and treating patients with neurological disorders.

Neurological disorders such as Parkinson’s disease, Alzheimer’s disease, and cerebral small vessel disease involve both motor and cognitive impairments. These conditions are characterized by a prolonged course and insidious progression, leading to widespread underdiagnosis and undertreatment.

The widespread issues of delayed diagnosis and undertreatment stem from the fact that the diagnosis of neurological disorders relies primarily on clinicians’ subjective judgment.

During routine clinical practice, physicians make subjective judgments by taking medical histories, analyzing semi-quantitative classic scales such as the MMSE and MoCA completed by patients, and relying on their own experience. This diagnostic approach, due to its reliance on empirical clinical judgment, is associated with high uncertainty and a high rate of missed diagnoses.

Zhongke Ruiyi’s R&D achievements have brought about a disruptive transformation in diagnostic methods. Two solutions—quantitative assessment of cognitive function and quantitative assessment of motor function—break through conventional approaches, enabling quantitative characterization of patients’ neurological function.

Dr. Fan Xiangmin, CEO of Zhongke Ruiyi and an expert under the Chinese Academy of Sciences’ “Hundred Talents Program,” stated, “The Institute of Software, Chinese Academy of Sciences, has collaborated with Peking Union Medical College Hospital for many years, accumulating a substantial amount of quantitative data on neurological function. When the data volume is sufficiently large, we can analyze the population distribution of neurological disorders, disease patterns, and the progression of diseases and aging. These distributions and developmental patterns will help more people to prevent conditions in advance, achieve timely diagnosis, and pursue active treatment.”

Therefore, Zhongke Ruiyi aims to introduce two solutions—quantitative assessment of cognitive function and quantitative assessment of motor function—as infrastructure for hospital neurology departments. By leveraging database data, the company seeks to establish a gold standard for neurological function assessment, providing clinicians with quantitative analytical tools for screening, diagnosis, treatment, and follow-up.

Currently, both of its solutions are scheduled to initiate multicenter clinical trials in 2021, while simultaneously pursuing Class III medical device registration. By integrating quantitative assessments of cognitive and motor functions into assisted diagnosis, the company aims to expand application scenarios such as health check-ups and elderly care, thereby benefiting a broader population.

Lenovo Capital and Incubator Group (LCIG), the global technology industry fund under Lenovo, aims to integrate Lenovo’s global resources to shape the future of technology through investment and incubation. LCIG focuses on investments in the technology sector, with key areas including IoT, edge computing, cloud computing, big data, artificial intelligence, AI-enabled industries, and consumption upgrades. To date, LCIG has invested in nearly 150 outstanding companies, including listed companies and unicorns such as Meituan Dianping, CATL, NIO, Cambricon, Zhejiang Supcon, Megvii, BYD Semiconductor, Shenzhen Transportation, Zhuhai CosMX, Missfresh, SmartSens, Tuhu Car Care, and SmartMore.

ZhenFund is an early-stage investment firm co-founded by Mr. Xu Xiaoping and Mr. Wang Qiang in partnership with Sequoia Capital China in 2011, with total assets under management exceeding USD 1 billion. Since its inception, ZhenFund has been actively seeking out the most outstanding entrepreneurial teams and epoch-defining investment opportunities in sectors such as the internet, mobile internet, future technologies, artificial intelligence, enterprise services, healthcare, mass consumer markets, and education. The firm has invested in more than 700 startups, accompanying many from their early stages to unicorn status, including Xingsheng Youxuan, Meicai, Xiaohongshu (Little Red Book), Nuro, VIPKID, Yitu Technology, Shuidi Huzhu, Hero Entertainment, Horizon Robotics, Momenta, Zhaogang.com, Luoji Siwei (Get), Hesai Technology, Mobvoi, Mia.com, and XtalPi.

Changjian Investment Management (Beijing) Co., Ltd. was jointly established by a high-caliber team from Benjian Investment and Ivy Capital. Rooted in the Zhongguancun Innovation Demonstration Zone in Beijing, it is a venture capital firm dedicated to investing in talented entrepreneurial teams within China’s innovative technology and creative content sectors. Adhering to the long-term philosophy of building a “research-oriented + service-oriented” fund management model, the company’s business encompasses equity investment fund management across seed, angel, and venture capital stages, as well as incubation, consulting, and advisory services for portfolio companies. The Changjian Investment team boasts over 20 years of professional experience in investment banking, possesses in-depth knowledge of China’s capital markets, and extends its business coverage to include merger and acquisition funds and industrial investment funds.